SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Mobileye Global, Inc. engages in the business of developing and deploying driver assistance systems and autonomous driving technologies and solutions. It operates under the Mobileye and Other segments. The company was founded by Amnon Shashua and Ziv Aviram in 1999 and is headquartered in Jerusalem, Israel.

Mobileye Global Inc - Ordinary Shares - Class A

MOBILEYE GLOBAL INC

Mobileyes shares have sold off to a 52-week low despite a quarterly earnings beat and a modest outlook increase. Bearish traders point to declining revenue, questions about profit quality and concerns over competition and advanced-driver-assistance-system execution, while bulls cite the companys cash position and buyback authorization.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. The firm offers annealing and gate-model quantum computing technologies. It provides professional services that assist customers in identifying and implementing quantum computing applications and selling quantum computer systems to customers. The company was founded by Eric Ladizinsky in 1999 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

QBTS is drawing attention amid a steep selloff and repeated lows, as traders debate whether the decline reflects broader weakness in speculative quantum stocks or concerns about D-Waves valuation, cash burn and the pace of commercialization. Some see the drop as a buying opportunity, while others expect further downside, with bearish options activity adding to the cautious tone.

Basic Attention Token (BAT) is a cryptocurrency launched in 2017and operates on the Ethereum platform. Basic Attention Token has a current supply of 1,500,000,000 with 1,495,724,656.95260575 in circulation. The last known price of Basic Attention Token is 0.13064027 USD and is up 2.94 over the last 24 hours. It is currently trading on 591 active market(s) with $15,372,551.09 traded over the last 24 hours. More information can be found at https://basicattentiontoken.org/.

Basic Attention Token

BAT is drawing attention after a sharp rally and perceived technical breakout, with traders highlighting its relative strength and debating whether momentum can continue or give way to profit-taking and a pullback. No single confirmed token-specific catalyst dominates; some traders point to broader altcoin momentum and Braves expanding ecosystem as supporting narratives.

Air Canada engages in the provision of airline transportation services. Its services cover full-service airline, scheduled passenger and cargo services, serving more than two hundred airports on six continents. It operates through the following geographical segments: Canada, U.S. Transborder, Atlantic, Pacific, and Other. The company was founded on April 11, 1936 and is headquartered in Saint-Laurent, Canada.

Air Canada Inc. - Ordinary Shares (Voting and Variable Voting)

Air Canada Inc.

Air Canadas latest earnings and outlook are driving attention: traders acknowledge strong revenue and demand but focus on surging fuel costs and reduced guidance as pressures on profitability. Some remain bullish on share buybacks and Aeroplans value, while others argue the results and fuel outlook justify the selloff.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

A major Binance security breach has rattled crypto markets and weighed on Bitcoin-linked MSTR, prompting bearish concerns about crypto confidence and further selling alongside dip-buying and hopes for a rebound. Traders are also debating Q3 results, with some noting that reported earnings were largely driven by Bitcoin gains while software revenue fell short of expectations.

United States Natural Gas Fund LP. - United States Natural Gas Fund

United States Natural Gas Fund, LP

Natural gas futures have slid as mild-weather and warm-winter forecasts point to weaker heating demand, with traders also citing ample inventories and supply. Some remain bearish, while others are buying the dip ahead of winter and watching for colder forecasts that could prompt a sharp rebound.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

A strong third-quarter report and raised full-year sales outlook, fueled by demand for Mounjaro and Zepbound, have driven LLYs breakout to record highs. Traders are mostly bullish on continued GLP-1 growth and analyst upgrades, while some question the valuation and flag lower profit guidance and Foundayos slower launch.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in São Paulo, Brazil.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Nu is selling off alongside Brazilian equities after Lulas reelection, as traders reassess Brazils political and economic outlook rather than point to company-specific news. Many view the drop as an overreaction and buying opportunity, while others cite fiscal-policy concerns and Nus exposure to Brazil as risks.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Mineralys Therapeutics Inc

AstraZenecas early Baxfendy launch sales have disappointed traders and renewed concerns about payer access, competition, and Mineralys ability to commercialize lorundrostat independently. Some argue hypertension launches take time to build coverage and prescribing, while others question the drugs sales potential; the FDA decision and clinical milestones remain key points of focus.

Karman Holdings, Inc. engages in the design, testing, manufacturing, and sale of dependable missile systems. It offers Payload Protection & Deployment Systems, Aerodynamic Interstage Systems, and Propulsion Systems. The company was founded on August 20, 2020 and is headquartered in Huntington Beach, CA.

Karman Holdings Inc.

Karman Holdings Ord Shs

KRMN is drawing attention amid a rebound in defense and drone stocks, with traders pointing to rotation out of tech and optimism around defense demand; some are also positioning ahead of earnings. Fridays pullback was attributed by one trader to a broad market sell-off, while others debated whether the recent strength can hold.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

S&P 500, Nasdaq End Third Straight Week Lower As Investors Move Away From Tech, AI — AMZN, INTC, LLY, RBLX In Focus

Prediction: $100 per Month Invested in Eli Lilly (LLY) Stock Will Be Worth This Much by 2030

Key PointsEli Lilly stock has been on a tear, averaging annual gains of more than 30...

Elon Musk Says Eli Lilly Has 'Some Banger Drugs Coming Out' After CEO Dave Ricks Bets Against Vinod Khosla's Big Biotech Skepticism

Elon Musk praises Eli Lilly's upcoming drug pipeline as CEO Dave Ricks responds to skepticism about innovation at big biotech companies.read more...

Cathie Wood Loads Up On TEM, ILMN And Biotech Stocks — But Pares Stake In This Pharma Giant That Had A Blowout Q3

Equity

Ark Invest increased its exposure to several widely followed biotechnology stocks during the session.

S&P 500, Nasdaq End Third Straight Week Lower As Investors Move Away From Tech, AI —  AMZN, INTC, LLY, RBLX In Focus

The S&P 500 and Nasdaq 100 ended the week down 0.6% and 2%, respectively. 



LLY, ABBV Stocks Hit All-Time High – Here’s What’s Driving Investor Enthusiasm Today

LLY shares extended gains on bullish Wall Street action after the company raised its full-year 2026 outlook.

Eli Lilly Is Now Worth as Much as Warren Buffett's Berkshire Hathaway. Can the Rally Keep Going?

Key PointsBerkshire Hathaway's market cap is roughly the same as Eli Lilly's, at about $1.1 trillion...

Eli Lilly 'Deserves' Stock Upside: Analyst

Eli Lilly beats Q3 estimates on Mounjaro and Zepbound growth. Analysts lift price targets as 2026 revenue guidance jumps to $92 billion.read more...

VKTX: Is a 2029 Launch for Its Obesity Drug Within Reach?

Viking Therapeutics is set to target a potential first-half 2029 launch for VK2735, but clinical readouts, FDA review and intensifying competition could shape its timeline.

LLY Q3 Earnings Call Highlights Raised Outlook and Obesity Drug Growth

Eli Lilly raises its 2026 revenue outlook as Mounjaro and Zepbound sales surge, Medicare access expands and Foundayo gains traction despite pricing pressures.

LLY Stock Hits Record as CEO Says Middle-Income Consumers Are Driving Pharma's 'Largest New Category Expansion'

Eli Lilly stock hits a record close as CEO David Ricks points to middle-income demand and a historic pharma category expansion.read more...

$LLY Q3 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of $7.48 up 6.55% YoY
• Reported revenue of $24.4B up 38.61% YoY
• Lilly raised 2026 revenue guidance to $91B and updated performance margin guidance to 52.0% to 52.5%; full-year non-GAAP EPS guidance is $35.00 to $36.00.

Stocktwits

 Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of $7.48 up 6.55% YoY
• Reported revenue of $24.4B up 38.61% YoY
• Lilly raised 2026 revenue guidance to $91B and updated performance margin guidance to 52.0% to 52.5%; full-year non-GAAP EPS guidance is $35.00 to $36.00.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

• Reported GAAP EPS of $7.48 up 6.55% YoY
• Reported revenue of $24.4B up 38.61% YoY
• Lilly raised 2026 revenue guidance to $91B and updated performance margin guidance to 52.0% to 52.5%; full-year non-GAAP EPS guidance is $35.00 to $36.00.

Lilly reported a 15% decrease in realized prices, $4.2B in acquired IPR&D charges, and dependence on relatively few products and a consolidated supply chain as risks.

Lilly reported Mounjaro and Zepbound revenue increases, multiple U.S. FDA approvals, and positive topline Phase 3 retatrutide trial results in adults with type 2 diabetes.

Extremely Bullish Sentiment

<ul class="summary-bullets"><li>ARK's actively managed ETFs made a mix of moves, trimming some established holdings while adding to smaller healthcare names.</li><li>ARK Genomic Revolution ETF increased its exposure to Tempus AI, Pacific Biosciences of California, Beam Therapeutics, and Arcturus Therapeutics.</li><li>Eli Lilly was among ARK’s notable trims on Friday, with its flagship ARK Innovation ETF paring its position despite Lilly’s blowout third-quarter performance.</li></ul>Cathie Wood’s ARK Invest made a series of moves across its actively managed ETFs on Friday, with the firm adding to several healthcare, genomics and cryptocurrency stocks.ARK's actively managed ETFs made a mix of moves, trimming some established holdings while adding to smaller healthcare names. Several stocks appeared in more than one fund.<h2 class="st-heading-2">ARK Loads Up On Biotech Stocks</h2>Tempus AI Inc. (TEM) was one of ARK’s more prominent biotech-related purchases. ARK added 61,114 shares through ARK Genomic Revolution ETF (ARKG) and another 93,407 shares through ARK Innovation ETF (ARKK), increasing its exposure to the AI-powered healthcare and genomics company across two funds.Illumina Inc. (ILMN) was another significant addition, with ARKK buying 43,130 shares of the genomics sequencing company.ARKG also added to several other biotechnology names, buying 133,767 shares of Pacific Biosciences of California Inc. (PACB), 22,687 shares of Beam Therapeutics Inc. (BEAM) and 64,483 shares of Arcturus Therapeutics Holdings Inc. (ARCT). ARKK separately bought another 346,507 shares of Pacific Biosciences.Outside healthcare and genomics, ARK added to Circle Internet Group Inc. (CRCL) and Coinbase Global Inc. (COIN) across multiple ETFs. ARK Blockchain &amp; Fintech Innovation ETF (ARKF) also bought 13,757 shares of Robinhood Markets Inc. (HOOD).<h2 class="st-heading-2">ARK’s Surprise Sell</h2>Eli Lilly &amp; Co. (LLY) was among the notable positions ARK pared on Friday. ARK’s flagship ARKK ETF sold 17,626 shares of the pharmaceutical giant.The move came after Lilly reported third-quarter results that topped expectations, with the company continuing to benefit from strong demand for its diabetes and obesity medicines.ARK also reduced its exposure to CareDx Inc. (CDNA), with the ARKG ETF selling 50,859 shares.Bullish (BLSH) was another recurring sell. ARK sold shares of the crypto-focused financial services company through ARKF, ARKK and ARKW, with the trades totaling more than 238,000 shares across the three ETFs.<a href="https://stocktwits.com/symbol/ARKG">ARKG’s price</a> fell nearly 7% in Friday’s regular trading session. Retail sentiment on Stocktwits around ARKG trended in the ‘bullish’ territory at the time of writing.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/l3-harris-ba-report-record-backlogs-hii-raises-shipbuilding-revenue/cZUKNB8R9cf">Stocktwits Defense Watch: L3Harris, BA Report Record Backlogs, HII Raises FY2026 Shipbuilding Revenue Forecast</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cathie Wood, Founder & CEO, Ark Invest, speaks during the second day of the FII PRIORITY Summit held at the Faena Hotel on February 20, 2025 in Miami Beach, Florida. (Photo by Joe Raedle/Getty Images)

Arcturus Therapeutics Holdings Inc

ARK Fintech Innovation ETF

ARK Investment Management LLC - ARK Genomic Revolution ETF

ARK Innovation ETF

ARK Next Generation Internet ETF

Beam Therapeutics Inc

Caredx Inc

Coinbase Global Inc

Circle

Robinhood Markets Inc

Illumina Inc

Pacific Biosciences of California Inc

Tempus AI Inc

$AMD

$SHOP

$UBER

$LLY

$AMD, $SHOP, $UBER, and $LLY are four of the most searched and talked-about stocks among retail investors this morning. Which are you most bullish on? Drop your reasoning in the comments.

Which of these trending stocks are you most bullish on for the next 5 years - $AMD, $SHOP, $UBER, or $LLY? 
 
Explain why in the comments.

Advanced Micro Devices Inc

Shopify Inc

Uber Technologies Inc

Which of these trending stocks are you most bullish on for the next 5 years - 

Stocktwits Polls

Massive earnings beat and a major upward revision to full-year revenue guidance fueled by dominant demand for metabolic medications.

Positive Phase 3 trial results for retatrutide demonstrating superior weight loss and A1C reduction compared to leading alternatives.

Investors are actively lobbying for a stock split as shares reach all-time highs and the market cap continues to climb toward $1.5T.

Management is signaling aggressive long-term expansion into oncology, immunology, and neuroscience to diversify away from weight-loss drugs.

Rumors and analyst discussions point to the potential for strategic acquisitions of smaller biotech firms to fortify the research pipeline.

Feed

News

Sentiment

Earnings

Futures

Fundamentals

Info

LLY Futures

LLY Single Stock Futures